Vipadenant

Vipadenant
Clinical data
Other names	BG-14; BG14; BIIB-014; BIIB014; BIIB14; CEB-4520; V-2006; VER-11135; VER-A00-11; VER-A00049; VER-ADO-49; VR-2006
Routes of; administration	Oral
Drug class	Adenosine A2A receptor antagonist; Antiparkinsonian agent
ATC code	None;
Identifiers
	IUPAC name 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine;
CAS Number	442908-10-3;
PubChem CID	21874557;
IUPHAR/BPS	5612;
DrugBank	DB06625;
ChemSpider	10620930;
UNII	LDR3USH1NJ;
KEGG	D09991;
ChEMBL	ChEMBL447664;
PDB ligand	9XT (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID90196103 ;
Chemical and physical data
Formula	C16H15N7O
Molar mass	321.344 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC(=C1)CN2C3=NC(=NC(=C3N=N2)C4=CC=CO4)N)N;
	InChI InChI=1S/C16H15N7O/c1-9-7-10(4-5-11(9)17)8-23-15-14(21-22-23)13(19-16(18)20-15)12-3-2-6-24-12/h2-7H,8,17H2,1H3,(H2,18,19,20); Key:HQSBCDPYXDGTCL-UHFFFAOYSA-N;

Vipadenant (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name BIIB014 and others) is an adenosine A_2A receptor antagonist which was under development for the treatment of Parkinson's disease and cancer but was never marketed.^[1]^[2]^[3]^[4] It is taken orally.^[1] The drug was first described in the scientific literature by 2006.^[5]^[6] It was under development by Vernalis, Biogen, and Juno Therapeutics.^[1]^[2] Vipadenant reached phase 2 clinical trials prior to the discontinuation of its development.^[1]^[2]

References

^ ^a ^b ^c ^d ^e "Vipadenant". AdisInsight. 28 October 2024. Retrieved 28 January 2026.
^ ^a ^b ^c Terry M (24 January 2026). "Delving into the Latest Updates on Vipadenant with Synapse". Synapse. Retrieved 28 January 2026.
^ Pinna A (May 2014). "Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued". CNS Drugs. 28 (5): 455–474. doi:10.1007/s40263-014-0161-7. PMID 24687255.
^ Brooks DJ, Papapetropoulos S, Vandenhende F, Tomic D, He P, Coppell A, et al. (2010). "An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers". Clinical Neuropharmacology. 33 (2): 55–60. doi:10.1097/WNF.0b013e3181d137d2. PMID 20375654.
^ Lightowler, S., Knight, A. R., & Upton, R. (2006). Pharmacology of BIIB014/V2006, an A2A antagonist for the treatment of PD. Targeting Adenosine A2A Receptors in Parkinson’s Disease and Other CNS Disorders. Boston, USA. https://scholar.google.com/scholar?cluster=5861921750099200903
^ Gillespie RJ, Bamford SJ, Botting R, Comer M, Denny S, Gaur S, et al. (January 2009). "Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines". Journal of Medicinal Chemistry. 52 (1): 33–47. doi:10.1021/jm800961g. PMID 19072055.